<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2862</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"> http://dx.doi.org/10.31782/IJCRR.2020.121717</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Low Dose Magnesium Sulphate Regime for Eclampsia and Imminent Eclampsia&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Laddad</surname><given-names>Manisha M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Patil</surname><given-names>Anjali</given-names></name></contrib><contrib contrib-type="author"><name><surname>Havale</surname><given-names>P. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vhawal</surname><given-names>S.S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ashitosh</surname><given-names>Bahulekar</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>8</day><month>09</month><year>2020</year></pub-date><volume>7)</volume><issue/><fpage>120</fpage><lpage>123</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Introduction: In India especially in rural areas, the majority of eclampsia cases report to hospital in an emergency. They are unregistered with inadequate antenatal care and travel a long distance before reaching the hospital as the rural health centres are not sufficiently equipped to manage this condition. Aim: To determine the efficacy of low dose magnesium sulphate in eclampsia and imminent eclampsia. To measure serum levels of magnesium with this regime. To correlate serum magnesium levels and efficacy. To identify complications of magnesium sulphate therapy in the mother and the baby. Methods: 120 cases of preeclampsia and eclampsia were allotted by simple random sampling technique to two groups i.e. low dose regime group and Pritchard regime group. It was observed that the majority of the cases were unbooked (90%) and were in the age group of 21-25 years (76.6%). Results: Study observed that eclampsia was primarily a disease of primigravida (61%). Most women in the study group had a bodyweight of fewer than 50 kgs (74%). The average total dose of magnesium sulphate required was 20 grams i.e. 54.5% less than that required in standard Pritchard regime. Majority of the cases (90%) responded to the low dose regime with the recurrence rate being (10%) as compared to Pritchard regime group being (91.6%) and recurrence being 8.33%. The success rate for seizure prophylaxis in imminent eclampsia being 100% in both the groups. The average serum magnesium levels low dose regime in sample 1 was 3.36__ampersandsignplusmn;0.76 and 3.30__ampersandsignplusmn;0.69 for sample 2. The therapeutic serum magnesium levels for the present low dose regime being 2.61 to 4.05 mg/dl. The cost of therapy while doing so was reduced to less than half with low dose regime than that of Pritchard regime. The perinatal mortality was 30% with low dose regime. Conclusion: Low dose magnesium sulphate regime was effective in seizure prophylaxis in imminent eclampsia patients and as effective as Pritchard regime in eclampsia patients. The dose required for control of convulsions was less than half used in Pritchard regime and even cost of therapy was half than Pritchard regime..&#13;
</p></abstract><kwd-group><kwd>Low Dose</kwd><kwd> Magnesium Sulphate</kwd><kwd> Eclampsia</kwd><kwd> Imminent Eclampsia</kwd><kwd> Seizure prophylaxis</kwd></kwd-group></article-meta></front></article>
